Validea Joseph Piotroski Strategy Daily Upgrade Report

Validea’s Book/Market Investor model, which implements Joseph Piotroski’s accounting-based value screen, upgraded AZENTA INC (AZTA) and NOV INC (NOV) from 0% to 80%, signaling the strategy has some interest in both names based on recent fundamentals and valuation. AZTA cleared most Piotroski tests — book/market, ROA and its improvement, operating cash flow, cash vs. net income, lower long-term debt/assets, gross margin and asset turnover — but failed on change in current ratio and shares outstanding, indicating stronger profitability and cash generation offset by liquidity and dilution concerns. NOV also met the majority of tests (book/market, ROA, operating cash flow, cash vs. net income, current ratio, share issuance, gross margin and asset turnover) but failed on change in ROA and long-term debt/assets, suggesting improved operating metrics alongside mixed leverage and profitability trends. Quant and value investors should view these upgrades as a prompt for deeper fundamental and valuation review rather than immediate conviction, given the nuances in liquidity, leverage and ROA dynamics.

Analysis

Validea's Book/Market Investor model upgraded AZENTA INC (AZTA) and NOV INC (NOV) from 0% to 80% under a Piotroski-based screen, where an 80% score denotes the strategy has some interest while >90% would indicate strong interest. The model flagged improvements in book-to-market, operating cash flow and several profitability and efficiency metrics for both names, while the general sentiment output is mildly positive (score 0.3) and estimated market impact is low (0.25).

AZTA passed book/market, return on assets (and its improvement), operating cash flow, cash vs. net income, reduced long-term debt/assets, gross margin and asset turnover but failed on change in current ratio and change in shares outstanding; the firm is a life-sciences sample management and multiomics services provider, so the failures point to near-term liquidity pressure and potential dilution despite stronger operating fundamentals.

NOV passed many operational tests but failed on change in ROA and change in long-term debt/assets; as an oilfield equipment and services provider, the result signals improving operating metrics offset by weakening profitability trend or higher leverage.

The upgrade warrants targeted fundamental follow-up and valuation work rather than immediate conviction given liquidity, dilution and leverage caveats identified by the Piotroski tests.

Key Decisions for Investors

• Treat the 80% upgrades as a screening signal to add AZTA and NOV to a watchlist rather than initiating full-sized positions
• For AZTA, prioritize review of current ratio trends, share issuance history and near-term cash runway before increasing exposure
• For NOV, focus due diligence on recent ROA trajectory and debt maturities or covenant risk given the failed leverage test
• Use the Piotroski findings as a prompt for valuation sensitivity analysis and event-driven catalysts (earnings, cash flow releases) prior to committing capital